Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.

摘要

In patients with multiple myeloma (MM), the use of donor lymphocyte infusion (DLI) after allo-SCT is well established to induce a graft-versus-myeloma reactivity. Response rates of 30-50% in relapsed MM patients have been reported. Several studies have shown that the novel agents in the treatment of MM bortezomib, thalidomide and lenalidomide, besides their anti-myeloma effect, also have immune-modulating effects that may enhance the graft-versus-myeloma reaction.